Viking Therapeutics corrects statement on VK2735 oral maintenance trial dosing schedule
VKTX•Viking Therapeutics corrected its Oct. 6, 2026 release, which incorrectly said the VK2735 maintenance trial would evaluate weekly oral doses. The trial will evaluate daily oral doses, selected subcutaneous schedules or placebo.
1. Corrected dosing schedule
Viking Therapeutics said the trial will evaluate maintenance options including daily oral doses, selected subcutaneous schedules or placebo. Its earlier release incorrectly stated that the study would evaluate weekly oral doses.
